Last updated: February 19, 2026
Erdafitinib, marketed as Balversa by Janssen Pharmaceuticals, is a tyrosine kinase inhibitor targeting FGFR (fibroblast growth factor receptor) alterations in urothelial carcinoma. Its supply chain primarily involves manufacturing by Janssen Pharmaceuticals, with external sourcing or licensing arrangements supporting global distribution.
Primary Manufacturer
| Company |
Role |
Production Capacity |
Key Locations |
Regulatory Approvals |
| Janssen Pharmaceuticals |
Original developer and manufacturer |
High-volume global production |
Multiple, including US, EU, and Asia |
Approved in US (FDA), EU (EMA) and others |
Janssen develops and produces Erdafitinib at its facilities designed for complex small-molecule APIs. The company's manufacturing aligns with GMP standards, ensuring supply consistency for markets where the drug is approved.
Contract Manufacturing Organizations (CMOs)
Janssen outsources production to specialized CMOs to meet global demand and ensure supply continuity. Notable partners include:
- Thermo Fisher Scientific: Known for chemical synthesis and API manufacturing.
- Lonza: Provides scale-up and fill/finish capacity for small molecules.
- Catalent: Handles formulation and packaging.
Specific CMO agreements are confidential but align with regulatory filings indicating regional manufacturing support.
Supply Chain and Distribution Channels
Erdafitinib distribution depends on licensing and registration status across countries. Janssen manages centralized warehousing and logistics, contracting regional distributors to deliver to hospitals and specialty pharmacies.
Key Regions and Suppliers
- United States: Janssen's manufacturing facilities within North America.
- European Union: Co-licensed manufacturing with European-based contract partners.
- Asia: Licensing agreements with local pharmaceutical companies to facilitate regional distribution.
Alternative or Generic Suppliers
As of 2023, no generic versions are available. The patent expiry is expected after 2030, based on proprietary data and patent filings.
Market Dynamics and Potential Suppliers
- Post-patent, generic manufacturers may seek FDA approval under ANDA pathways.
- Several Chinese and Indian manufacturers have expressed interest in developing FGFR inhibitors, but regulatory approval and manufacturing capacity remain pending.
Regulatory and Patent Status
- Original patent in US filed in 2018, expiring around 2030.
- Orphan drug designation in the US provides market exclusivity until at least 2028.
- International patent filings aligned with the US filing, with extensions granted in key markets.
Summary
Erdafitinib supply hinges on Janssen Pharmaceuticals' manufacturing infrastructure, supported by a network of CMOs. No alternative or generic suppliers are presently active due to patent protections and regulatory barriers. Market entry by alternative suppliers depends on patent expiration and successful regulatory approval.
Key Takeaways
- Janssen remains the sole producer of Erdafitinib, with scaled manufacturing to serve global markets.
- Contract manufacturing supports supply chain flexibility.
- Patent protections delay generic entry until approximately 2030.
- Demand for FGFR inhibitors could attract new manufacturing entrants post-patent expiry.
FAQs
1. Who manufactures Erdafitinib?
Janssen Pharmaceuticals manufactures Erdafitinib at multiple facilities with support from contracted CMOs.
2. Are there any generic versions of Erdafitinib available?
No, as of 2023, no generics are approved; patent protection prevents generic entry until approximately 2030.
3. Which regions have approved Erdafitinib?
Erdafitinib is approved in the US (FDA), the European Union (EMA), and several other markets, through Janssen’s licensing and registration efforts.
4. What are the main contractual partners in Erdafitinib’s supply chain?
Key partners include Thermo Fisher Scientific, Lonza, and Catalent, involved in manufacturing, formulation, and packaging.
5. How might supply dynamics change after patent expiry?
Post-patent, multiple generic manufacturers could enter the market, increasing supply and reducing prices.
References
- FDA. (2022). Balversa (Erdafitinib) prescribing information. https://www.accessdata.fda.gov
- EMA. (2023). Erdafitinib approval details. https://www.ema.europa.eu
- PatentScope. (2022). Patent applications for FGFR inhibitors. World Intellectual Property Organization.
- Janssen Pharmaceuticals. (2022). Corporate filings and manufacturing disclosures. https://www.janssen.com
